Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ata ur Rehman Quraishi, MBBS"'
Autor:
Andrew Caddell, MD, FRCPC, Daniel Belliveau, MD, FRCPC, Andrew Moeller, MD, FRCPC, Ata ur Rehman Quraishi, MBBS, FCPS
Publikováno v:
CJC Open, Vol 4, Iss 4, Pp 390-394 (2022)
Background: The disposition of patients presenting with ST-elevation myocardial infarction (STEMI) is commonly the coronary care unit. Recent studies have suggested that low-risk STEMI patients could be managed in a lower-acuity setting immediately a
Externí odkaz:
https://doaj.org/article/3cf4d0ada5774a1dbec534eb90a99f2c
Autor:
Dennis T. Ko, MD, MSc, Tareq Ahmed, MPH, Peter C. Austin, PhD, Warren J. Cantor, MD, Paul Dorian, MD, Michael Goldfarb, MD, MSc, Yanyan Gong, MSc, Michelle M. Graham, MD, Jing Gu, MD, PhD, Nathaniel M. Hawkins, MD, MPH, MBChB, Thao Huynh, MD, PhD, Karin H. Humphries, MBA, DSc, Maria Koh, MSc, Yoan Lamarche, MD, MSc, Laurie J. Lambert, PhD, Patrick R. Lawler, MD, MPH, Jean-Francois Légaré, MD, Hung Q. Ly, MD, Feng Qiu, MSc, Ata ur Rehman Quraishi, MBBS, Derek Y. So, MD, MSc, Robert C. Welsh, MD, Harindra C. Wijeysundera, MD, PhD, Graham Wong, MD, MPH, Andrew T. Yan, MD, FRCPC, Yana Gurevich, MD, MPH
Publikováno v:
CJC Open, Vol 3, Iss 8, Pp 1051-1059 (2021)
ABSTRACT: Background: Given changes in the care and outcomes of acute myocardial infarction (AMI) patients over the past several decades, we sought to develop prediction models that could be used to generate accurate risk-adjusted mortality and readm
Externí odkaz:
https://doaj.org/article/e1f4d1cbaf33463d98fa3d331f7b003f
Autor:
Wan Cheol Kim, MD, FRCPC, DRCPSC, Gregory Hirsch, MD, FRCSC, Catherine Kells, MD, FACC, FRCPC, FCCS, Ata-Ur-Rehman Quraishi, MBBS, FACC, FCPS, Helen Bishop, MD, FRCPC, Bakhtiar Kidwai, MBBS, MSc, MRCPI, Lawrence Title, MD, FRCPC, Hussein Beydoun, MBBS, FRCPC, FACC, Navjot Sandila, BSc, MPH, Wael Sumaya, MD, PhD, MRCP, Osama Elkhateeb, MD, FACC, FRCPC, DRCPSC
Publikováno v:
CJC Open, Vol 6, Iss 3, Pp 548-555 (2024)
Background: The study assessed the outcomes of patients undergoing percutaneous coronary intervention (PCI) to bypass grafts, focusing on all-cause mortality and target vessel failure (TVF) rates. Methods: A single-centre registry analysis included 3
Externí odkaz:
https://doaj.org/article/b401f53b7b4a4d5ba984052d3e86e466
Autor:
Felipe H. Valle, MD, PhD, Shaun G. Goodman, MD, MSc, Mary Tan, MSc, Andrew Ha, MD, Samer Mansour, MD, Robert C. Welsh, MD, Andrew T. Yan, MD, Kevin R. Bainey, MD, MSc, Stephane Rinfret, MD, Brian J. Potter, MDCM SM, Razi Khan, MD, Gerald Simkus, MD, Madhu K. Natarajan, MD, J.D. Schwalm, MD, Benoit Daneault, MD, Mark J. Eisenberg, MD, MPH, Joseph Abunassar, MD, Bryan Har, MD, MPH, Jean Gregoire, MD, Jean-Francois Tanguay, MD, Christopher B. Overgaard, MD, Jean-Pierre Dery, MD, Robert De Larochelliere, MD, Jean-Michel Paradis, MD, Mina Madan, MD, MHS, Basem Elbarouni, MBBCh, Derek Y.F. So, MD, Ata-Ur-Rehman Quraishi, MBBS, Akshay Bagai, MD, MHS
Publikováno v:
CJC Open, Vol 3, Iss 12, Pp 1419-1427 (2021)
Background: In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), selecting an antithrombotic regimen requires balancing risks of ischemic cardiac events, stroke, and bleeding. Methods: We studied 467 patients
Externí odkaz:
https://doaj.org/article/eb37fce9ac584e069aa2601948f5239b